BOLT BOLT BIOTHERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BOLT BIOTHERAPEUTICS INC reported revenue of $5.00K (down 99.7% from a year earlier), net income of −$7.72M and diluted EPS of −$4.57; over the last four quarters revenue was $4.70M and net income −$28.7M; for the fiscal year ended December 2025 revenue was $7.70M, up 0.1% on the year before.
BOLT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $7.70M, gross profit n/a, operating income −$36.1M, net income −$33.4M (margin -433.7%), EPS −$17.85
- Fiscal year ended Dec 2024: revenue $7.69M, gross profit n/a, operating income −$73.0M, net income −$63.1M (margin -820.8%), EPS −$33.06
- Fiscal year ended Dec 2023: revenue $7.88M, gross profit n/a, operating income −$76.2M, net income −$69.2M (margin -878.6%), EPS −$1.83
- Fiscal year ended Dec 2022: revenue $5.73M, gross profit n/a, operating income −$90.3M, net income −$88.1M (margin -1537.8%), EPS −$2.36
- Fiscal year ended Dec 2021: revenue $1.26M, gross profit n/a, operating income −$92.8M, net income −$98.6M (margin -7824.7%), EPS −$2.97
BOLT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $5.00K (down 99.7% year over year), net income −$7.72M, EPS −$4.57
- Quarter ended Mar 31, 2026: revenue $26.0K (down 97.9% year over year), net income −$7.24M, EPS −$4.31
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.50M, net income −$6.63M, EPS −$3.91
- Quarter ended Sep 30, 2025: revenue $2.17M (up 90.1% year over year), net income −$7.14M, EPS −$3.72
- Quarter ended Jun 30, 2025: revenue $1.80M (up 41.5% year over year), net income −$8.56M, EPS −$4.46
- Quarter ended Mar 31, 2025: revenue $1.22M (down 76.8% year over year), net income −$11.0M, EPS −$5.76
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$15.9M, EPS −$13.73
- Quarter ended Sep 30, 2024: revenue $1.14M (down 54.9% year over year), net income −$15.2M, EPS −$7.93
- Quarter ended Jun 30, 2024: revenue $1.28M (down 11.0% year over year), net income −$21.2M, EPS −$11.12
- Quarter ended Mar 31, 2024: revenue $5.27M (up 188.8% year over year), net income −$10.8M, EPS −$0.28
- Quarter ended Dec 31, 2023 (from the annual report): revenue $2.09M (up 48.1% year over year), net income −$17.9M, EPS −$0.47
- Quarter ended Sep 30, 2023: revenue $2.53M (up 19.7% year over year), net income −$16.3M, EPS −$0.43
- Quarter ended Jun 30, 2023: revenue $1.43M (up 2.9% year over year), net income −$18.1M, EPS −$0.48
- Quarter ended Mar 31, 2023: revenue $1.83M (up 124.6% year over year), net income −$17.0M, EPS −$0.45
- Quarter ended Dec 31, 2022 (from the annual report): revenue $1.41M, net income −$20.0M, EPS −$0.53
- Quarter ended Sep 30, 2022: revenue $2.11M (up 180.9% year over year), net income −$21.8M, EPS −$0.58
- Quarter ended Jun 30, 2022: revenue $1.39M, net income −$22.7M, EPS −$0.61
- Quarter ended Mar 31, 2022: revenue $813K, net income −$23.7M, EPS −$0.64
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$27.2M, EPS −$0.56
- Quarter ended Sep 30, 2021: revenue $752K, net income −$23.4M, EPS −$0.63
BOLT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$39.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$61.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$69.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$76.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$57.1M, share buybacks n/a
BOLT balance sheet
- Jun 30, 2026: cash $12.9M, total assets $40.3M, total liabilities $27.7M, shareholders' equity $12.6M
- Mar 31, 2026: cash $11.6M, total assets $48.0M, total liabilities $28.2M, shareholders' equity $19.8M
- Dec 31, 2025: cash $11.7M, total assets $56.7M, total liabilities $30.2M, shareholders' equity $26.5M
- Sep 30, 2025: cash $17.8M, total assets $65.1M, total liabilities $33.0M, shareholders' equity $32.1M
- Jun 30, 2025: cash $9.60M, total assets $75.5M, total liabilities $36.7M, shareholders' equity $38.8M
- Mar 31, 2025: cash $8.39M, total assets $85.9M, total liabilities $39.1M, shareholders' equity $46.8M
- Dec 31, 2024: cash $7.21M, total assets $99.6M, total liabilities $42.4M, shareholders' equity $57.2M
- Sep 30, 2024: cash $9.37M, total assets $109M, total liabilities $37.3M, shareholders' equity $72.0M
What is BOLT's revenue?
BOLT BIOTHERAPEUTICS INC reported $4.70M of revenue over its last four quarters, through June 30, 2026.
Is BOLT profitable?
No. BOLT BIOTHERAPEUTICS INC lost $28.7M over the last four quarters.
What is BOLT's EPS?
Diluted earnings per share over the last four quarters were −$16.51; −$4.57 in the latest quarter.